EuroPCR 2017: Xeltis' Regenerated Heart Valve Shows Promising Early Preclinical Data

17 May 2017

• By Catherine Longworth

It may still be early days but Xeltis' second product from its Endogenous Tissue Restoration platform technology, an aortic valve scaffold, is showing promising results in animal studies. The data, presented at EuroPCR, showed that the bioresorbable aortic valve had good hemodynamic performance and fully functional valves in vivo six months after implantation.

Anatomy of Human Heart — Xeltis presented positive early data from preclinical studies at EuroPCR in Paris • Source: Shutterstock

Emerging structural heart disease specialist Xeltis has presented positive early data from preclinical studies that showed its bioabsorbable aortic heart valve implant was "fully functional" in vivo six-months after implantation. These results were presented at a dedicated plenary session on bioresorbable valve therapy at EuroPCR on May 17 in Paris.

Laurent Grandidier, CEO of Xeltis told Medtech Insight the results were "very encouraging and positive."